ATXI · Avenue Therapeutics, Inc.

The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 111,209 shares were granted by the Issuer to the reporting Person for the 2025 annual dividend.

The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the receipt of proceeds by the Issuer upon the exercise of warrants previously issued by the Issuer.

Effective April 26, 2024, the Issuer effected a one-for-seventy-five reverse stock split of its common stock (the "Reverse Stock Split") and the amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.

Effective April 26, 2024, the Issuer effected a one-for-seventy-five reverse stock split of its common stock (the "Reverse Stock Split") and the amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.

Effective April 26, 2024, the Issuer effected a one-for-seventy-five reverse stock split of its common stock (the "Reverse Stock Split") and the amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.

Represents an award of 65,000 restricted stock units which will vest in equal installments at September 30, 2024, December 31, 2024, September 23, 2025, and September 23, 2026. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and the consummation of a Change in Control event (as defined in the Avenue Therapeutics, Inc. 2015 Incentive Plan); the amount will be distributed in the form of the Issuer's common stock.

The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027.

The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027.

The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027.

Represents an award of 170,000 restricted stock units which will vest in equal installments at September 30, 2024, December 31, 2024, September 23, 2025, and September 23, 2026. The shares underlying the restricted stock units will not be settled until the earlier of the tenth business day of January of the year following certain terminations of service of the Reporting Person from the Issuer and Change in Control events (as defined in the Avenue Therapeutics, Inc. 2015 Incentive Plan); the amount will be distributed in the form of the Issuer's common stock.

The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027.

The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2025; (ii) one-third of the shares subject to the option vest on January 1, 2026; and (iii) one-third of the shares subject to the option vest on January 1, 2027.

The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 413,507 shares were granted by the Issuer to the Reporting Person following the closing of an equity financing.

The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 415,728 shares were granted by the Issuer to the Reporting Person following the closing of an equity financing.

The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 1,685,768 shares were granted by the Issuer to the Reporting Person for the 2023 annual dividend.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.13 to $0.15, inclusive. Each sale price was below the purchase prices for the shares, and the reporting person engaged in the transactions for tax purposes and to cause his holdings to fall below 10% of the outstanding shares of the issuer's common stock and thereby cease being subject to the requirements of Section 16 of the Securities Exchange Act of 1934. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.13 to $0.15, inclusive. Each sale price was below the purchase prices for the shares, and the reporting person engaged in the transactions for tax purposes and to cause his holdings to fall below 10% of the outstanding shares of the issuer's common stock and thereby cease being subject to the requirements of Section 16 of the Securities Exchange Act of 1934. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above.

Consists of shares of commons stock held in accounts maintained for the benefit of certain individuals or trusts over which the Reporting Person has shared dispositive authority.

Consists of shares of common stock held in a joint account with the Reporting Person's wife.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.13 to $0.15, inclusive. Each sale price was below the purchase prices for the shares, and the reporting person engaged in the transactions for tax purposes and to cause his holdings to fall below 10% of the outstanding shares of the issuer's common stock and thereby cease being subject to the requirements of Section 16 of the Securities Exchange Act of 1934. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above.

Consists of shares of common stock held in trusts for the benefit of the Reporting Person's children in which the Reporting Person is the trustee.

Consists of shares of common stock held by the Reporting Person's wife.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.13 to $0.15, inclusive. Each sale price was below the purchase prices for the shares, and the reporting person engaged in the transactions for tax purposes and to cause his holdings to fall below 10% of the outstanding shares of the issuer's common stock and thereby cease being subject to the requirements of Section 16 of the Securities Exchange Act of 1934. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above.

Consists of shares of common stock held in accounts maintained for the benefit of certain individuals or trusts over which the Reporting Person has shared voting and dispositive authority.

The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2024; (ii) one-third of the shares subject to the option vest on January 1, 2025; and (iii) one-third of the shares subject to the option vest on January 1, 2026.

Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.

The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2024; (ii) one-third of the shares subject to the option vest on January 1, 2025; and (iii) one-third of the shares subject to the option vest on January 1, 2026.

Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.

The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2024; (ii) one-third of the shares subject to the option vest on January 1, 2025; and (iii) one-third of the shares subject to the option vest on January 1, 2026.

Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.

The option vests in accordance with the following schedule: (i) 25% of the shares subject to the option vest on August 1, 2023; (ii) 25% of the shares subject to the option vest on August 1, 2024; (iii) 25% of the shares subject to the option vest on August 1, 2025; and (iv) 25% of the shares subject to the option vest on August 1, 2026.

Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.

The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2024; (ii) one-third of the shares subject to the option vest on January 1, 2025; and (iii) one-third of the shares subject to the option vest on January 1, 2026.

Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.

The option vests in accordance with the following schedule: (i) one-third of the shares subject to the option vest on January 1, 2024; (ii) one-third of the shares subject to the option vest on January 1, 2025; and (iii) one-third of the shares subject to the option vest on January 1, 2026.

Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.

The option vests in accordance with the following schedule: (i) 25% of the shares subject to the option vest on August 1, 2023; (ii) 25% of the shares subject to the option vest on August 1, 2024; (iii) 25% of the shares subject to the option vest on August 1, 2025; and (iv) 25% of the shares subject to the option vest on August 1, 2026.

The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing.

The Reporting Person is entitled to an annual dividend on its outstanding Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the 2022 annual dividend.

Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.

The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing.

Effective September 22, 2022, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.

This Form 4 is being jointly filed on behalf of (i) InvaGen Pharmaceuticals Inc., a New York corporation ("InvaGen"), (ii) Cipla (EU) Limited, a company incorporated in the United Kingdom ("Cipla EU"), and (iii) Cipla Limited, a company incorporated in India ("Cipla Limited") (each of InvaGen, Cipla EU and Cipla Limited, a "Reporting Person", and collectively, the "Reporting Persons"). InvaGen is a wholly-owned direct subsidiary of Cipla EU. Cipla EU is a wholly-owned direct subsidiary of Cipla Limited. Because of the relationship of InvaGen to Cipla EU and Cipla Limited, each such Reporting Person may be deemed to beneficially own the securities covered by this Form 4.

On September 22, 2022, the common stock of Avenue Therapeutics, Inc. (the "Issuer") reverse split 1-for-15, resulting in the 5,833,333 shares of common stock of the Issuer previously reported by the Reporting Persons becoming 388,888 shares of common stock of the Issuer.

On October 11, 2022, pursuant to the terms of the previously announced Stock Repurchase Agreement, dated July 25, 2022, among InvaGen, Fortress Biotech, Inc. and the Issuer, the Issuer repurchased 388,888 shares of common stock of the Issuer from InvaGen for an aggregate purchase price of $3,000,000 (the "Share Repurchase").

This restricted stock award (RSA) vests on December 17, 2024, three years after the date granted.

This restricted stock award (RSA) vests on March 15, 2022.

Includes 85,668 shares of restricted stock.

This restricted stock award (RSA) vests on December 17, 2024, three years after the date granted.

This RSA vests on March 15, 2022.

Includes 85,668 shares of restricted stock.

This restricted stock unit award (RSU) vests on March 15, 2022. Each restricted stock unit is equivalent to one share of the Company's common stock.

Includes 411,616 RSUs.

This restricted stock unit award (RSU) vests on March 15, 2022. Each RSU is equivalent to one share of the Company's common stock.

Includes 100,505 RSUs.

This restricted stock award (RSA) vests on December 17, 2024, three years after the date granted.

On September 15, 2021, a total of 7,160 shares were sold by the Company at a weighted average sales price of $1.62 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.

Includes 67,997 shares of restricted stock.

On August 20, 2020, a total of 3,840 shares were sold by the Company at a weighted average sales price of $12.13 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.

Common Stock vests upon the earliest to occur of the following: (i) Grantee's death or disability; (ii) a change in control of Avenue Therapeutics, Inc.; or (iii) the Second Stage Closing with InvaGen.

Includes 84,663 shares of restricted stock.

Common Stock vests upon the earliest to occur of the following: (i) Grantee's death or disability; (ii) a change in control of Avenue Therapeutics, Inc.; or (iii) the Second Stage Closing with InvaGen.

Includes 84,663 shares of restricted stock.